Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Neoadjuvant immune checkpoint therapy: Enabling insights into fundamental human immunology and clinical benefit

Cancer Cell(2025)10.1016/j.ccell.2025.03.005Source: DataRank Database

Neoadjuvant immune checkpoint therapy: Enabling insights into fundamental human immunology and clinical benefit is a research paper published in Cancer Cell (2025). On theSindex it has a DataRank of 0. It has been cited 12 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access12 citations

Download PDF

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (6 grants)Impact (FWCI 6.53)OA: greenTopics (22)IDs (PubMed, PMC, OpenAlex)Annotations (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (4)

Omar Alhalabi ORCID,Sangeeta Goswami ORCID,Padmanee Sharma ORCID,Kristen E. Pauken ORCID

Live enrichment

PubMed:40118048 PMC:PMC13143226 OpenAlex:https://openalex.org/W4408684190

Foundation for the National Institutes of Health

Grant: R37 CA279192-01

Foundation for the National Institutes of Health

Grant: R01 CA283402-01

NCI NIH HHS

Grant: R37 CA279192

NCI NIH HHS

Grant: R01 CA283402

Conquer Cancer Foundation

University of Texas MD Anderson Cancer Center

FWCI

6.53

Citation Percentile

1.0%

Citation Trend

2025

2026

greenLicense: https://doi.org/10.15223/policy-004

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC13143226/

publisherhttps://api.elsevier.com/content/article/PII:S1535610825000844?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1535610825000844?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.ccell.2025.03.005

Fields of Study

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesCAR-T cell therapy research

MeSH Terms

Immune Checkpoint InhibitorsClinical Trials as TopicHumansImmunotherapyNeoplasmsDrug Resistance, NeoplasmNeoadjuvant Therapy

Keywords

Immune checkpointImmune systemImmunologyMedicineImmunotherapyCTLA-4BiomarkersPD-1Clinical TrialsNeoadjuvantHuman ImmunologyImmune Checkpoint Therapy

Neoadjuvant immune checkpoint therapy: Enabling insights into fundamental human immunology and clinical benefit

FAIR Checklist

Authors (4)

Funding (6 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)